低分子肝素治疗实验室监测现状.doc

低分子肝素治疗实验室监测现状 血管病学进展20o7年第28卷第4期AdvCardiovascDis.July2oo7,Vo1.28.No.4 [1] [2] [3] [4] [5] [6] [参考文献] SombergJ,WeinbergerJ.Latestentthrombosis:problemornot[J]?AmJCar- diol,2007,99:1020—1023. JaffeR,StraussBH.Lateandverylatethrombosisofdrug—elutingstents[J].J AmCoilCardiol,2007,50:inpress. CutlipDE.BaimDS,HoKK.eta1.Stentthrombosisintllemodernera:a pooledanalysisofmulticentercoronarystontclinicaltrials[J].Circulation, 2001,103:1967—1971. MorenoR,FernandezC,HernandezR,eta1.Drug—elutingstentthrombosis: resultsfromapooledanalysisincluding10randomizedstudies[J].JAmColl Cardiol,2005,45:954-959. IakovouI,SchmidtT,BonizzoniE,eta1.Incidence,predictors,andoutcome ofthrombosisaftersuccessfulimplantationofdrug—elutingstents[J].JAMA, 2005,293:2126-2130. OngAT,HoyeA,AokiJ,eta1.Thirty—dayincidenceandsix—monthclinical [7] [8] [9] [10] ? 517? outcomeofthromboticstentocchsionafterbare—rIletal,sirolimus,orpaclitaxel stentimplantation[J].JAmCoilCardiol,2005,45:947-953. CuflipDE,WindeckerS,MehranR,eta1.Clinicalendpointsincorollarystent tIi也:acaseforstandardizeddefinitions[J].Circulation,2007,115:2344— 2351. LascherTF,SteffelJ,EberliFR,eta1.Drug—elutingste~tandcoronarythrom? bosisbiologicalmechanismsandclinicalimplications[J].Circulation.2007, 27:105—1058. VirmaniR,GuagliumiG,FarbA,eta1.Localizedhypersensitivityandlate coronarythrombosissecondarytoasirolimus.-elutingstent:shouldwebecau— tious[J]?Circulation,2004,109:701-705. GrinesCL,BonowRO,CaseyDE,毗a1.Preventionofprematurediscontinua- tionofdualantiplatelettherapyinpatientswithcoronaryarterystents[J].J AmCoilCardiol,2007,49:734-739. 收稿日期:2007-06-20 (本文编辑:郭宪) 低分子肝素治疗实验室监测现状 史旭波胡大一综述 (首都医科大学附属北京同仁医院心脏中心,北京100730) StatusQuoofLaboratoryMonitoringof Low-molecularWeightHeparinTherapy SHIXu—bo,HUDa—yi (CardiovascularCenter,TongrenHospitalAffiliated 文章编号:1004-3934(2007)04-0517-04 toCapitalUniversityofMedicalSciences,Bering100730,China) 中图分类号:R973.2文献标识码:A 摘要:在急性冠脉综合征及静脉血栓栓塞等广泛领域低分子肝素正在逐步取代普通肝素成为主要主要抗凝药物.低分子肝 素抗凝治疗是否需要以及如何进行监测,近几年已成为争论的焦点.普通的抗凝治